Evolva Holding SA - Asset Resilience Ratio
Evolva Holding SA (EVE) has an Asset Resilience Ratio of 89.11% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read EVE total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2022)
This chart shows how Evolva Holding SA's Asset Resilience Ratio has changed over time. See EVE total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Evolva Holding SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see EVE market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF6.31 Million | 89.11% |
| Short-term Investments | CHF0.00 | 0% |
| Total Liquid Assets | CHF6.31 Million | 89.11% |
Asset Resilience Insights
- Very High Liquidity: Evolva Holding SA maintains exceptional liquid asset reserves at 89.11% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Evolva Holding SA Industry Peers by Asset Resilience Ratio
Compare Evolva Holding SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Evolva Holding SA (2013–2022)
The table below shows the annual Asset Resilience Ratio data for Evolva Holding SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 2.56% | CHF3.36 Million ≈ $4.24 Million |
CHF131.01 Million ≈ $165.63 Million |
-3.47pp |
| 2021-12-31 | 6.03% | CHF9.42 Million ≈ $11.91 Million |
CHF156.17 Million ≈ $197.45 Million |
-14.75pp |
| 2019-12-31 | 20.78% | CHF39.92 Million ≈ $50.47 Million |
CHF192.08 Million ≈ $242.84 Million |
-- |
| 2018-12-31 | 0.00% | CHF0.00 ≈ $0.00 |
CHF213.02 Million ≈ $269.31 Million |
-- |
| 2017-12-31 | 40.52% | CHF97.18 Million ≈ $122.87 Million |
CHF239.82 Million ≈ $303.20 Million |
+16.55pp |
| 2016-12-31 | 23.97% | CHF47.52 Million ≈ $60.07 Million |
CHF198.24 Million ≈ $250.62 Million |
+20.65pp |
| 2013-12-31 | 3.32% | CHF3.49 Million ≈ $4.42 Million |
CHF105.27 Million ≈ $133.09 Million |
-- |
About Evolva Holding SA
EvoNext Holdings SA is in the process of liquidation of its remaining assets. Previously, the company was engaged in discovery, research, development, and commercialization of nature-based ingredients for use in flavor and fragrances, health ingredients, health protection, and other sectors in Switzerland, the United States, and internationally. The company was formerly known as Evolva Holding SA… Read more